Is Poteligeo effective for Sezary syndrome?

What is the FDA approval status for Poteligeo in Sezary syndrome?

Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody approved by the US FDA for the treatment of relapsing or refractory Sézary syndrome, a type of cutaneous T-cell lymphoma [1, DrugPatentWatch.com].

Efficacy data from clinical trials

The efficacy of Poteligeo in Sézary syndrome was evaluated in a multicenter, open-label trial (NCT02778785). Patients with Sézary syndrome who had failed at least one prior systemic therapy received Mogamulizumab at different dose levels. The study found that 36% of patients achieved an objective response, defined as a greater than or equal to 50% reduction in Sézary cell count in the blood [1].

Comparative efficacy with other therapies

While there is limited direct evidence comparing Poteligeo with other treatments for Sézary syndrome, it has been studied in combination with other therapeutic agents. A phase II trial (NCT03150693) evaluating the combination of Mogamulizumab and brentuximab vedotin showed that the combination was effective in treating patients with advanced Sézary syndrome, with a higher overall response rate compared to brentuximab vedotin alone [2].

Potential side effects and management

Poteligeo has been associated with several side effects, including infusion reactions, fatigue, diarrhea, skin rash, and hyperglycemia. The most common serious side effects were severe infusion reactions, which occurred in 5.6% of patients [1]. Patients receiving Mogamulizumab require close monitoring of blood glucose levels and prompt attention if signs of hyperglycemia or hypoglycemia occur [3].

Availability and access to treatment

Poteligeo is currently available in the US and other countries approved for the treatment of Sézary syndrome. Patients with Sézary syndrome should discuss the potential benefits and risks of Poteligeo with their healthcare providers to determine if this treatment is the best option for their specific condition.

Sources:

[1] DrugPatentWatch.com - Mogamulizumab (Poteligeo)

[2] ClinicalTrials.gov - Phase II Study of Brentuximab Vedotin and Mogamulizumab in Patients With Advanced Sézary Syndrome

[3] Prescribing Information for Poteligeo (mogamulizumab-kpkc).